Ignite Creation Date:
2024-05-05 @ 11:40 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00100893
Status:
COMPLETED
Last Update Posted:
2015-06-08
First Post:
2005-01-06
Brief Title:
IH636 Grape Seed Extract in Preventing Breast Cancer in Postmenopausal Women at Risk of Developing Breast Cancer
Sponsor:
City of Hope Medical Center
Organization:
City of Hope Medical Center
Study Overview
Official Title:
A Phase I Prevention Trial of ACTIVIN Grape Seed Extract as an Aromatase Inhibitor In Healthy Postmenopausal Women at Risk for Breast Cancer
Status:
COMPLETED
Status Verified Date:
2015-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Chemoprevention is the use of certain drugs to keep cancer from forming growing or coming back The use of IH636 grape seed extract may prevent breast cancer
PURPOSE This phase I trial is studying the side effects and best dose of IH636 grape seed extract in preventing breast cancer in postmenopausal women at risk of developing breast cancer
PURPOSE This phase I trial is studying the side effects and best dose of IH636 grape seed extract in preventing breast cancer in postmenopausal women at risk of developing breast cancer
Detailed Description:
OBJECTIVES
Determine the efficacy of IH636 grape seed proanthocyanidin extract in terms of suppression of estrogen biosynthesis in healthy post-menopausal women at high risk of developing breast cancer
Determine the safety and tolerability of this dietary supplement in terms of symptoms and changes in markers of bone and lipid metabolism and in markers of nonspecific adrenal suppression in these participants
Determine preliminarily an optimum biologic dose of this dietary supplement as defined by suppression of serum estradiol in these participants
Determine a minimum duration of use of this dietary supplement to achieve aromatase inhibition in these participants
OUTLINE This is a pilot dose-finding placebo-controlled study
Participants receive oral placebo once or twice daily on days -14 to 0 Participants then receive oral IH636 grape seed proanthocyanidin extract once or twice daily on days 1-85 Treatment continues in the absence of toxicity
Cohorts of 6 participants receive one of four dose levels of IH636 grape seed proanthocyanidin extract up to an established safe dose
PROJECTED ACCRUAL A total of 24 participants will be accrued for this study within 12 months
Determine the efficacy of IH636 grape seed proanthocyanidin extract in terms of suppression of estrogen biosynthesis in healthy post-menopausal women at high risk of developing breast cancer
Determine the safety and tolerability of this dietary supplement in terms of symptoms and changes in markers of bone and lipid metabolism and in markers of nonspecific adrenal suppression in these participants
Determine preliminarily an optimum biologic dose of this dietary supplement as defined by suppression of serum estradiol in these participants
Determine a minimum duration of use of this dietary supplement to achieve aromatase inhibition in these participants
OUTLINE This is a pilot dose-finding placebo-controlled study
Participants receive oral placebo once or twice daily on days -14 to 0 Participants then receive oral IH636 grape seed proanthocyanidin extract once or twice daily on days 1-85 Treatment continues in the absence of toxicity
Cohorts of 6 participants receive one of four dose levels of IH636 grape seed proanthocyanidin extract up to an established safe dose
PROJECTED ACCRUAL A total of 24 participants will be accrued for this study within 12 months
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CDR0000407637 | REGISTRY | NCI PDQ | httpsreporternihgovquickSearchP30CA033572 |
| P30CA033572 | NIH | None | None |
| CHNMC-IRB-03178 | None | None | None |